Distribution, excretion and metabolic pathways of a single parenteral administration of kappa-opioid receptor agonist RU-1205
| Autor: | Olesya Iu. Grechko, Olga N. Zhukowskaia, Olga E. Syrvacheva, Alexander A. Spasov, A. I. Rashchenko, V. A. Anisimova, Anatoly S. Morkovnik, Natalya V. Eliseeva, Yuliya V. Lifanova, Lyudmila A. Smirnova |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Agonist
medicine.drug_class tissue distribution RM1-950 Pharmacology κ-opioid receptor Excretion 03 medical and health sciences 0302 clinical medicine Pharmacokinetics Biotransformation kappa-agonists medicine Distribution (pharmacology) Pharmacology (medical) Tissue distribution pharmacokinetic Chemistry Metabolic pathway 030220 oncology & carcinogenesis imidazobenzimidazoles analgesics excretion Therapeutics. Pharmacology biotransformation 030217 neurology & neurosurgery |
| Zdroj: | Research Results in Pharmacology, Vol 7, Iss 2, Pp 59-65 (2021) Research Results in Pharmacology 7(2): 59-65 |
| Popis: | Introduction: The purpose was to study the pharmacokinetic properties of RU-1205 with the previously identified kappa-agonistic and analgesic effects after parenteral administration. Materials and methods: Pharmacokinetic parameters of RU-1205 after intravenous and subcutaneous administration at doses of 10 mg/kg and 50 mg/kg, respectively, were investigated, using the method of high-performance liquid chromatography with measurement of the compound according to a pre-established calibration curve. The indices of the area under the pharmacokinetic curve, clearance, half-life, residence time of the drug molecule in the body, total (apparent) volume of distribution, as well as the indicator of absolute bioavailability for subcutaneous administration were calculated. Tissue distribution and excretion of RU-1205 were also studied. Evaluation of metabolism of RU-1205 was conducted in silico, using the PALLAS 3.00 software, with the use of specific tests with CYP 450 substrates and by studying the ability of RU-1205 to form conjugates with endogenous acids. Results and discussion: It was found that after a single intravenous administration, the investigated substance was determined in the blood for 12 h; the half-life was 8.49 hours. The absolute bioavailability after subcutaneous administration is 57.35%. RU-1205 is eliminated within 3–4 days. The main route of excretion is extrarenal. The biotransformation of the substance probably proceeds mainly with the formation of oxidized forms of the initial molecule according to the reactions of the first phase of metabolic transformation, so the chance to observe phase 2 of the metabolism could be very low. Conclusion: The test substance undergoes a long process of elimination, has the highest tropism to the elimination organs and undergoes active biotransformation processes in the body of animals. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|